Classes
DEA Class; Rx
Common Brand Names; Capoten, Captoril
- ACE Inhibitors
Description
Shortest acting, oral ACE inhibitor; contains a sulfhydryl group; side effects increase at higher doses; may be used for HTN, CHF, and various renal syndromes (e.g., diabetic nephropathy, proteinuria, scleroderma renal crisis).
Indications
Indicated for the treatment of hypertension
Contraindications
Hypersensitivity to ACE inhibitors
Anuria
History of ACEI-induced angioedema
Hereditary or idiopathic angioedema
Coadministration of neprilysin inhibitors (eg, sacubitril) with ACE inhibitors may increase angioedema risk; do not administer ACE inhibitors within 36 hr of switching to or from sacubitril/valsartan
Bilateral renal artery stenosis
Do not coadminister with aliskiren in patients with diabetes mellitus or with renal impairment (ie, GFR <60 mL/min/1.73 m²)
Adverse Effects
- Hyperkalemia (1-11%)
- Hypersensitivity rxns (4-7%)
- Skin rash (4-7%)
- Dysgeusia (2-4%)
- Hypotension (1-2.5%)
- Pruritus (2%)
- Cough (0.5-2%)
- Chest pain (1%)
- Palpitations (1%)
- Proteinuria (1%)
- Tachycardia (1%)
- Cardiac arrest
- Orthostatic hypotension
- Ataxia
- Confusion
- Depression
- Somnolence
- Angioedema
- Photosensitivity
- Neutropenia
- ARF if renal artery stenosis
- Renal impairment
- Impotence
Warnings
Aortic stenosis/hypertrophic cardiomyopathy, hypotension, biliary cirrhosis or biliary obstruction, myelosuppression, electrolyte imbalance, hyperuricemia or gout, SLE, hepatic or renal impairment
Avoid concomitant use with lithium
Less effective in African-Americans
Excessive hypotension if concomitant diuretics or volume-depleted; start with 6.25 mg q8hr
Risk of hyperkalemia, especially with K+ sparing diuretics
Dual blockade of the renin angiotensin system with ARBs, ACE inhibitors, or aliskiren associated with increased risk for hypotension, hyperkalemia, and renal function changes (including acute renal failure) compared to monotherapy
Blood levels don’t correlate with BP response
Food decreases absorption
ACE inhibition also causes increased bradykinin levels which putatively mediates angioedema
Coadministration with mTOR inhibitors (eg, temsirolimus, everolimus, sirolimus) may increase risk for angioedema
Intestinal angioedema, that presented with abdominal pain, reported in patients treated with ACE inhibitors
Neutropenia (<1000/mm³ with myeloid hypoplasia reported with captopril; risk is dependent on clinical status of patient
Causes false positive urine acetone
Pregnancy and Lactation
Pregnancy Category: C; D in 2nd & 3rd trimesters
Discontinue as soon as pregnancy detected; during the second and third trimesters of pregnancy, drugs that act directly on the renin-angiotensin have been associated with fetal injury that includes hypotension, neonatal skull hypoplasia, anuria, reversible or irreversible renal failure, and death
Lactation: enters breast milk/not recommended (AAP states compatible with nursing)
Maximum Dosage
450 mg/day PO.
450 mg/day PO.
Safety and efficacy have not been established; however, doses up to 6 mg/kg/day PO (Max: 450 mg/day) have been used off-label.
Safety and efficacy have not been established; however, doses up to 6 mg/kg/day PO (Max: 450 mg/day) have been used off-label.
Safety and efficacy have not been established; however, doses up to 6 mg/kg/day PO have been used off-label. A lower maximum of 1.5 mg/kg/day PO is recommended for congestive heart failure.
Safety and efficacy have not been established; however, doses up to 6 mg/kg/day PO have been used off-label. A lower maximum of 1.5 mg/kg/day PO is recommended for congestive heart failure.
How supplied
Captopril
tablet
- 12.5mg
- 25mg
- 50mg
- 100mg